Newsroom

Amiko receives CE mark for use of the Respiro Platform with Teva’s Spiromax® Inhaler, Chiesi’s Nexthaler® inhaler and GlaxoSmithKline’s Ellipta® inhaler London,

Amiko’s Respiro awarded with the 1st prize at the IBM Watson AI XPRIZE’s annual Milestone Awards Los Angeles, US. Dec. 8, 2017 — Amiko Digital Health Limited (Amiko),